Listen

Description

In this fast‑paced Psychopharm podcast, we break down the OCD medication algorithm for obsessive compulsive disorder. You will hear about pushing SSRI doses, switching to Luvox or clomipramine, adding low‑dose antipsychotics, and glutamate modulators such as N‑acetylcysteine and ondansetron. The conversation also demystifies BrainsWay H7 deep TMS, explains realistic expectations for symptom reduction, and stresses that exposure response prevention remains the centerpiece of care. Helpful for psychiatrists, NPs and trainees who want clinical pearls without the fluff.

NAC: https://drive.google.com/file/d/1b7ZBeFDKAAwLhfzUo0Jv58jEL7B70l5r/view

What we cover

* General principles: treat for about a year, higher doses tend to work better, trials last about eight weeks, and symptoms fall by roughly 30 to 40 percent. A six to eight point Y-BOCS drop is a good result.

* Why exposure and response prevention comes first, with medication for severe symptoms or patient preference, and a short look at inference-based CBT for those who cannot do ERP.

* SSRI steps: sertraline or escitalopram first, paroxetine avoided for weight gain, fluvoxamine (Luvox) as the usual switch after one or two failures, and raising doses while tracking the Y-BOCS.

* Augmentation: Brainsway H7 deep TMS (cleared as an adjunct in adults, with symptom provocation before each session), low-dose aripiprazole or risperidone, and the caution that clozapine and olanzapine can worsen obsessions and compulsions.

* Clomipramine, the clomipramine plus fluvoxamine combination (CYP1A2 rationale, serotonin toxicity risk), glutamatergic add-ons (lamotrigine, N-acetylcysteine, memantine, ondansetron, buspirone), exercise, and implants for the most disabled.

* Comorbidity: OCD that may reflect psychosis, bipolar disorder or autism, avoiding SSRIs where possible in bipolar disorder, and telling OCD from personality-driven obsessionality.

Clinical takeaways

* Use medication to make therapy possible. Score the Y-BOCS each visit and expect some movement within four to eight weeks at each dose step.

* Check which TMS is offered. The clearance is specific to the H7 coil and protocol, so a clinic using older equipment may not deliver it.

* Antipsychotic augmentation is common, but we favor lower-harm options first and monitor for new or worsening compulsions.

* N-acetylcysteine is usually targeted at 2.4 to 3 grams a day based on OCD studies. One steady brand is suggested because quality varies; taste, smell and GI upset can limit tolerance.

* In bipolar disorder with OCD symptoms, treat both poles first, since the OCD often eases. If a serotonergic drug is still needed, use a low dose on a stabilized mood.

* Check the obsessions. Genuine OCD has intrusive obsessions with unsatisfying compulsions, often at least an hour a day. Personality-driven obsessionality tends to feel satisfying or to communicate distress.

Read the full transcript

The complete transcript of this episode is on psycho.farm: Practical OCD Psychopharmacology: Evidence‑Based (& Non Evidence-Based) Medication Approach.

Related episodes

* What Is OCD? How to Understand It, Recognize It, and Treat It

* TMS for OCD: Effectiveness, Protocols, and Patient Selection

* Psychiatrist's Guide to Anxiety Medications: First Line to Last Resort

For education only. Not medical advice.



This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit psychofarm.substack.com